ArticleScientific reports2021
Preparation and characterization of nanocurcumin based hybrid virosomes as a drug delivery vehicle with enhanced anticancerous activity and reduced toxicity.
Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 47 citations in OpenAlex.
- Pentameric M2e influenza vaccine candidate generates strong immunity with limited survival benefit.Human vaccines & immunotherapeutics · 2026Article
- Curcumin-based nanotherapeutics for colibacillosis in chickens: advances in veterinary microbiology.Veterinary research communications · 2026Review
- An assessment of curcumin, curcumin spanlastics nanoparticles, and curcumin nanocrystals as possible drug delivery systems with antimicrobial, antioxidant, and antitumor activities.BMC biotechnology · 2026Article
- Prospective effect of mesenchymal exosomes versus nanocurcumin-loaded mesenchymal exosomes on induced periodontitis in albino rats.Odontology · 2026Article
- Nanoformulated Phytochemicals Against Pancreatic Cancer: Emerging Advances in Therapeutic Strategies.International journal of nanomedicine · 2026Review
- Virosomes: Beyond Vaccines.Life (Basel, Switzerland) · 2025Review
- Article
- Next-gen novel nanocage-based multivalent vaccine candidate to tackle the rising menace of Mpox.NPJ vaccines · 2025Article
- Synergistic anticancer efficacy of optimized curcumin-piperine loaded magnetic nanoparticles for the treatment of colorectal cancer.Exploration of targeted anti-tumor therapy · 2025Article
- Effect of curcumin nanoparticles on the number of preantral and antral follicles of white rats (Open veterinary journal · 2024Article
- Nanocurcumin-Based Sugar-Free Formulation: Development and Impact on Diabetes and Oxidative Stress Reduction.Nanomaterials (Basel, Switzerland) · 2024Article
- Physico-chemical properties of curcumin nanoparticles and its efficacy against Ehrlich ascites carcinoma.Scientific reports · 2023Article
- Innovative Phospholipid Carriers: A Viable Strategy to Counteract Antimicrobial Resistance.International journal of molecular sciences · 2023Review
- Nanoadjuvants: Promising Bioinspired and Biomimetic Approaches in Vaccine Innovation.ACS omega · 2023Review
- Development of a Self-Assembled Hydrogels Based on Carboxymethyl Chitosan and Oxidized Hyaluronic Acid Containing Tanshinone Extract Nanocrystals for Enhanced Dissolution and Acne Treatment.Pharmaceuticals (Basel, Switzerland) · 2022Article
- The Impact of Curcumin on Immune Response: An Immunomodulatory Strategy to Treat Sepsis.International journal of molecular sciences · 2022Review
- The theranostic potentialities of bioavailable nanocurcumin in oral cancer management.BMC complementary medicine and therapies · 2022Article
- Curcumin and Related Compounds in Cancer Cells: New Avenues for Old Molecules.Frontiers in pharmacology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The present study represents a formulation of nanocurcumin based hybrid virosomes (NC-virosome) to deliver drugs at targeted sites. Curcumin is a bioactive component derived from Curcuma longa and well-known for its medicinal property, but it exhibits poor solubility and rapid metabolism, which led to low bioavailability and hence limits its applications. Nanocurcumin was prepared to increase the aqueous solubility and to overcome all the limitations associated with curcumin. Influenza virosomes were prepared by solubilization of the viral membrane with 1,2-distearoyl-sn-glycerol-3-phosphocholine (DSPC). During membrane reconstitution, the hydrophilic nanocurcumin was added to the solvent system, followed by overnight dialysis to obtain NC-virosomes. The same was characterized using a transmission electron microscope (TEM) and scanning electron microscope (SEM), MTT assay was used to evaluate it's in vitro-cytotoxicity using MDA-MB231 and Mesenchyme stem cells (MSCs). The results showed NC-virosomes has spherical morphology with size ranging between 60 and 90 nm. It showed 82.6% drug encapsulation efficiency. The viability of MDA-MB231 cells was significantly inhibited by NC-virosome in a concentration-dependent manner at a specific time. The IC50 for nanocurcumin and NC-virosome was 79.49 and 54.23 µg/ml, respectively. The site-specific drug-targeting, high efficacy and non- toxicity of NC-virosomes proves its future potential as drug delivery vehicles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.